1Hofmockel G, Langer W, Theiss M, et al. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of IL-2, IFN-α and 5-Fu [J]. J Urol, 1996 (1):156:18.
2Blay J Y, Rossi J F, Wijdenes J, et al. Role of IL-2 in the paraneoplastic inflammatory syndrome associated with renalcell carcinoma [J]. Int J Cancer, 1997, 72(3): 424.
3Pectasides D, Varthalitis J, Kastopoulou M, et al. An outpatient phase Ⅱ study of subcutaneous IL-2 and IFN α-2b in combination with intravenous vinblastine in metastatic renal cell cancer[J]. Oncology, 1998, 55(1): 10.
4Long G D. Renal cell carcinoma[J]. Curr Opin Oncol, 1997, 9(3): 301.
5Facendola G.Subcutaneous administration of IL-2 and IFNα-2b in advanced renal cell carcinomas: a confirmatory study[J]. Br J Cancer, 1995,72: 1531.
6Liimmen G. Phase-Ⅱ study of IFN-7 verus IL-2 and IFNα-2b in metastatic renal cell carcinoma[J]. J Urol, 1996, 155:455.
7Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal cell carcinoma patients with autologous tumor cells and BCG: five-year results of a prospective randomized study[J]. Cancer, 1996, 77(12): 2560.
8Stadler W M. A phase Ⅱ trial of selectire radiotherapy (RT), GM-CSF and IL-2 in metastatic RCC[J]. Proc Annu Meet Am Soc Clin Oncol, 1997, 16: A1232.
9Gilboa E, Nair S K Lyerly H K. Immuotherapy of cancer with vaccines[J]. Cancer Immunol Immunother, 1998, 46: 82.
10Nestle F O, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells[J]. Nature Medicine, 1998(4): 328.